NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Oak Family Advisors LLC

Oak Family Advisors LLC lowered its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 87.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,612 shares of the medical research company's stock after selling 94,350 shares during the quarter. Oak Family Advisors LLC's holdings in NeoGenomics were worth $224,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. KBC Group NV lifted its holdings in shares of NeoGenomics by 44.7% in the 4th quarter. KBC Group NV now owns 6,557 shares of the medical research company's stock worth $108,000 after acquiring an additional 2,027 shares during the last quarter. Blue Trust Inc. raised its position in NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock valued at $73,000 after purchasing an additional 1,103 shares during the period. Mitsubishi UFJ Asset Management UK Ltd. lifted its stake in NeoGenomics by 16.7% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 56,000 shares of the medical research company's stock worth $923,000 after purchasing an additional 8,000 shares in the last quarter. Moody National Bank Trust Division boosted its position in shares of NeoGenomics by 20.2% during the fourth quarter. Moody National Bank Trust Division now owns 73,226 shares of the medical research company's stock worth $1,207,000 after buying an additional 12,314 shares during the period. Finally, Nordea Investment Management AB grew its stake in shares of NeoGenomics by 2.8% in the fourth quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company's stock valued at $1,301,000 after buying an additional 2,125 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.

NeoGenomics Stock Down 4.3 %

Shares of NEO traded down $0.60 during midday trading on Thursday, reaching $13.49. The stock had a trading volume of 803,846 shares, compared to its average volume of 1,119,173. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.99 and a quick ratio of 1.91. The company's fifty day simple moving average is $16.26 and its two-hundred day simple moving average is $15.68. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -22.11 and a beta of 1.23. NeoGenomics, Inc. has a 1-year low of $12.13 and a 1-year high of $19.11.

NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.04. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The company had revenue of $167.80 million for the quarter, compared to analysts' expectations of $167.00 million. During the same period last year, the firm earned ($0.06) earnings per share. NeoGenomics's quarterly revenue was up 10.5% on a year-over-year basis. Equities research analysts expect that NeoGenomics, Inc. will post -0.16 earnings per share for the current year.

Insider Transactions at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares of the company's stock, valued at $570,301.44. This trade represents a 12.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

NEO has been the topic of several research reports. Benchmark lowered NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. Needham & Company LLC reissued a "buy" rating and set a $19.00 price target on shares of NeoGenomics in a research report on Friday, January 10th. Bank of America lifted their price objective on shares of NeoGenomics from $18.00 to $19.00 and gave the company a "neutral" rating in a report on Friday, December 13th. Jefferies Financial Group began coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They set a "buy" rating and a $22.00 target price on the stock. Finally, The Goldman Sachs Group dropped their price target on shares of NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $20.20.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.